

PACIFIC EDGE BOARD CHANGES ANNOUNCED

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has today announced some changes to its Board, including the appointment of Chris Gallaher as an Independent Director, effective from 1st July 2016.

Chris is a senior corporate executive with a background in financial and general management and has had international experience in both public and private companies. He is the recently retired Group Chief Financial Officer for Fulton Hogan and has held senior executive and CEO roles with Vector, Village Roadshow, Carter Holt Harvey and was a partner in the chartered accounting firm Arthur Young with whom he started his career in Dunedin.

Chairman of Pacific Edge, Chris Swann, said: “Chris brings significant financial and risk management expertise to the company and will be a welcome addition to the Board. We have undertaken a review of the skills and expertise required as Pacific Edge continues to progress its commercialisation in the US and other targeted markets. Chris’s appointment, coupled with the recent appointment of US-based David Levison, brings further strength to the Board as we continue to help shape Pacific Edge’s future.”

Current Board member, Charles Sitch, has advised the Board of his intention to retire from the Board, effective immediately, due to increasing commitments in Australia. In addition, Chris Swann has announced his decision to retire at the next annual shareholders’ meeting on 25 August 2016 after more than a decade on the Board. Chris will retire by rotation and will not offer himself up for re-election.

Chris said: “It has been a rewarding and at times, challenging journey for Pacific Edge over the last ten years as the company has successfully transitioned from a research-based start up to a commercial entity. I am confident that the company is in good shape going forward, with a strong Board and management team.”

About Chris Gallaher

Chris is a senior executive with extensive financial and general management expertise. A New Zealander based in Melbourne, his career has been spent within large international companies in a range of financial and senior management roles, where he worked closely with company Boards and Audit Committees. He also serves on the Board of The Good Shepherd New Zealand and the investment committee of property development company, Substancia Pty Ltd. Chris is a Chartered Accountant and holds a BCom from Otago University and is a member of the Australian Institute of Company Directors.

ENDS

For more information contact:

David Darling
Executive Director and CEO
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW

www.pacifedge.co.nz

www.pacifedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to www.cxbladder.com for more information.